Judy W M Cheng

Summary

Affiliation: Long Island University
Country: USA

Publications

  1. ncbi request reprint L-arginine in the management of cardiovascular diseases
    J W Cheng
    Arnold and Marie Schwartz College of Pharmacy and Health Sciences, 75 DeKalb Ave, Brooklyn, NY 11201 5497, USA
    Ann Pharmacother 35:755-64. 2001
  2. ncbi request reprint Infection and atherosclerosis--focus on cytomegalovirus and Chlamydia pneumoniae
    J W Cheng
    Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY 11201, USA
    Ann Pharmacother 32:1310-6. 1998
  3. ncbi request reprint Recognition, pathophysiology, and management of acute myocardial infarction
    J W Cheng
    Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY, USA
    Am J Health Syst Pharm 58:1709-18; quiz 1719-21. 2001
  4. ncbi request reprint Cytochrome p450-mediated cardiovascular drug interactions
    J W Cheng
    Arnold and Marie Schwartz College of Pharmacy and Sciences, Long Island University, Brooklyn, New York, USA
    Heart Dis 2:254-8. 2000
  5. ncbi request reprint Bosentan
    Judy W M Cheng
    Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, and Mount Sinai Medical Center, New York, NY 10029, USA
    Heart Dis 5:161-9. 2003
  6. ncbi request reprint Nesiritide: review of clinical pharmacology and role in heart failure management
    Judy W M Cheng
    Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University and Mount Sinai Medical Center, New York, NY 10029, USA
    Heart Dis 4:199-203. 2002
  7. ncbi request reprint Pharmacotherapeutic options for the management of myocardial infarction
    Judy W M Cheng
    Mount Sinai Medical Center, One Gustave L Levy Place, Box 1211, New York, NY 10029, USA
    Expert Opin Pharmacother 3:1153-68. 2002
  8. ncbi request reprint Fondaparinux: a new antithrombotic agent
    Judy W M Cheng
    Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, New York, New York, USA
    Clin Ther 24:1757-69; discussion 1719. 2002
  9. doi request reprint Updates on cytochrome P450-mediated cardiovascular drug interactions
    Judy W M Cheng
    Arnold and Marie Schwartz College of Pharmacy and Sciences, Long Island University, Brooklyn, NY, USA
    Am J Ther 16:155-63. 2009
  10. ncbi request reprint Use of non-aspirin nonsteroidal antiinflammatory drugs and the risk of cardiovascular events
    Judy W M Cheng
    Long Island University, New York, NY, USA
    Ann Pharmacother 40:1785-96. 2006

Detail Information

Publications28

  1. ncbi request reprint L-arginine in the management of cardiovascular diseases
    J W Cheng
    Arnold and Marie Schwartz College of Pharmacy and Health Sciences, 75 DeKalb Ave, Brooklyn, NY 11201 5497, USA
    Ann Pharmacother 35:755-64. 2001
    ..To examine the role of L-arginine in the management of cardiovascular diseases...
  2. ncbi request reprint Infection and atherosclerosis--focus on cytomegalovirus and Chlamydia pneumoniae
    J W Cheng
    Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY 11201, USA
    Ann Pharmacother 32:1310-6. 1998
    ..e, cytomegalovirus and Chlamydia pneumoniae) in atherogenesis, and studies supporting the potential beneficial effects of antibiotics or antiviral agents in the management of atherosclerotic disease...
  3. ncbi request reprint Recognition, pathophysiology, and management of acute myocardial infarction
    J W Cheng
    Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY, USA
    Am J Health Syst Pharm 58:1709-18; quiz 1719-21. 2001
    ..Greater understanding of the pathophysiology of ACS has led to strategies to limit the progression of atherosclerosis and to improve survival and function after an acute event...
  4. ncbi request reprint Cytochrome p450-mediated cardiovascular drug interactions
    J W Cheng
    Arnold and Marie Schwartz College of Pharmacy and Sciences, Long Island University, Brooklyn, New York, USA
    Heart Dis 2:254-8. 2000
    ....
  5. ncbi request reprint Bosentan
    Judy W M Cheng
    Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, and Mount Sinai Medical Center, New York, NY 10029, USA
    Heart Dis 5:161-9. 2003
    ..Therefore, it is anticipated that numerous drug interactions may occur. Patients should be advised to consult their physicians or pharmacists should they need to consume other prescription or nonprescription medications...
  6. ncbi request reprint Nesiritide: review of clinical pharmacology and role in heart failure management
    Judy W M Cheng
    Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University and Mount Sinai Medical Center, New York, NY 10029, USA
    Heart Dis 4:199-203. 2002
    ..On-going studies target the examination of its long-term effects on mortality and morbidity and its pharmacoeconomic benefits to the healthcare system...
  7. ncbi request reprint Pharmacotherapeutic options for the management of myocardial infarction
    Judy W M Cheng
    Mount Sinai Medical Center, One Gustave L Levy Place, Box 1211, New York, NY 10029, USA
    Expert Opin Pharmacother 3:1153-68. 2002
    ....
  8. ncbi request reprint Fondaparinux: a new antithrombotic agent
    Judy W M Cheng
    Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, New York, New York, USA
    Clin Ther 24:1757-69; discussion 1719. 2002
    ....
  9. doi request reprint Updates on cytochrome P450-mediated cardiovascular drug interactions
    Judy W M Cheng
    Arnold and Marie Schwartz College of Pharmacy and Sciences, Long Island University, Brooklyn, NY, USA
    Am J Ther 16:155-63. 2009
    ..The principles in predicting drug interactions are also discussed...
  10. ncbi request reprint Use of non-aspirin nonsteroidal antiinflammatory drugs and the risk of cardiovascular events
    Judy W M Cheng
    Long Island University, New York, NY, USA
    Ann Pharmacother 40:1785-96. 2006
    ....
  11. ncbi request reprint Effect of nesiritide on renal function: a retrospective review
    Judy W M Cheng
    Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY 10029, USA
    Curr Med Res Opin 21:1857-63. 2005
    ..This study examined the effect of nesiritide on RF in patients evaluated in this NUE...
  12. ncbi request reprint Rosuvastatin in the management of hyperlipidemia
    Judy W M Cheng
    Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, New York, USA
    Clin Ther 26:1368-87. 2004
    ....
  13. ncbi request reprint Efficacy of glycoprotein IIb/IIIa-receptor inhibitors during percutaneous coronary intervention
    Judy W M Cheng
    Long Island University, Mount Sinai Medical Center, Box 1211, One Gustave L Levy Place, New York, NY 10029 6574, USA
    Am J Health Syst Pharm 59:S5-14. 2002
    ..Large clinical trials strongly support the use of abciximab or eptifibatide, but not tirofiban, in patients undergoing PCI...
  14. ncbi request reprint A review of isosorbide dinitrate and hydralazine in the management of heart failure in black patients, with a focus on a new fixed-dose combination
    Judy W M Cheng
    Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, New York, USA
    Clin Ther 28:666-78. 2006
    ..When used with nitrates, hydralazine (HYD) acts as an antioxidant and prevents development of nitrate tolerance...
  15. pmc Use of biological based therapy in patients with cardiovascular diseases in a university-hospital in New York City
    Larisa Chagan
    Division of Pharmacy Practice, Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, New York, USA
    BMC Complement Altern Med 5:4. 2005
    ..This survey also assessed the perceptions of users regarding the safety/efficacy of BBT, types of BBT used and potential BBT-drug interactions...
  16. ncbi request reprint Tezosentan in the management of decompensated heart failure
    Judy W M Cheng
    Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, New York, NY 10029, USA
    Cardiol Rev 13:28-34. 2005
    ..Clinical studies demonstrated mixed results for tezosentan regarding its efficacy and tolerability in the management of decompensated heart failure. The role or tezosentan in treating heart failure is yet to be defined...
  17. ncbi request reprint Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor
    LilyAnn Jeu
    Pharmacy Services, Veterans Affairs Medical Center, Bronx, New York, USA
    Clin Ther 25:2352-87. 2003
    ....
  18. ncbi request reprint Use of erythropoietin in heart failure management
    Krista Caiola
    Mount Sinai Hospital, New York, NY 10029, USA
    Ann Pharmacother 38:2145-9. 2004
    ..To review the use of erythropoietin for anemia in heart failure (HF)...
  19. ncbi request reprint Ranolazine for the management of coronary artery disease
    Judy W M Cheng
    Department of Pharmacy Practice, Long Island University, Brooklyn, New York, USA
    Clin Ther 28:1996-2007. 2006
    ..Ranolazine is a new class of antianginal agent. Unlike standard antianginal agents, it alters glucose and fatty acid metabolism for a different approach to the management of coronary artery disease...
  20. ncbi request reprint Glucose-insulin-potassium solution for acute myocardial infarction
    Jeffrey L Janiger
    Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, New York, NY, USA
    Ann Pharmacother 36:1080-4. 2002
    ..To review the role of glucose-insulin-potassium (GIK) solution in the management of acute myocardial infarction (AMI)...
  21. ncbi request reprint Key articles and guidelines in pharmacotherapeutic management of arrhythmias
    Judy W M Cheng
    Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, New York, New York, USA
    Pharmacotherapy 24:248-79. 2004
    ..This list should be useful not only to practitioners and trainees in cardiovascular pharmacotherapy, but also to other clinicians as an update...
  22. ncbi request reprint Use of alternative pharmacotherapy in management of cardiovascular diseases
    Larisa Chagan
    Shore Health System, Easton, MD, USA
    Am J Manag Care 8:270-85; quiz 286-8. 2002
    ..To review use of alternative pharmacotherapy (AP) in patients with cardiovascular disease (CVD) and significant drug interactions between AP and traditional CVD medications...
  23. ncbi request reprint Early experiences and clinical implications of drug-eluting stents: part 1
    Pang H Chong
    University of Illinois at Chicago, Chicago, IL, USA
    Ann Pharmacother 38:661-9. 2004
    ..To review the pathogenesis of in-stent restenosis and the evolution of drug-eluting stents (DES)...
  24. ncbi request reprint Drug therapy recommendations from the 2005 ACC/AHA guidelines for treatment of chronic heart failure
    Patricia A Howard
    Department of Pharmacy Practice, University of Kansas Medical Center, Kansas City, KS 66160 7231, USA
    Ann Pharmacother 40:1607-17. 2006
    ....
  25. doi request reprint Vernakalant in the management of atrial fibrillation
    Judy W M Cheng
    Massachusetts College of Pharmacy and Health Sciences, Brigham and Women s Hospital, Boston, MA 02115, USA
    Ann Pharmacother 42:533-42. 2008
    ..To review the pharmacology and clinical evidence of the use of vernakalant in the management of atrial fibrillation (AF)...
  26. doi request reprint Pharmacoeconomic review of medical management of persistent asthma
    Judy W M Cheng
    Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA
    Allergy Asthma Proc 29:109-22. 2008
    ..Future economic analysis should focus on finding better ways to evaluate productivity lost due to asthma, in addition to hospitalization...
  27. doi request reprint Ambrisentan for the management of pulmonary arterial hypertension
    Judy W M Cheng
    Massachusetts College of Pharmacy and Health Sciences and Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Clin Ther 30:825-33. 2008
    ....
  28. ncbi request reprint Early experiences and clinical implications of restenosis and drug-eluting stents: Part 2
    Pang H Chong
    University of Illinois at Chicago, Chicago, IL, USA
    Ann Pharmacother 38:845-52. 2004
    ..To review early clinical experience and future implications of drug-eluting stents (DES) in percutaneous coronary interventions...